



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
2653/56

Application Number
10/070,665

Filing date
December 16, 2002

Examiner
Minh Tam B. Davis

Art Unit
1642

Invention Title
POLYSIALIC ACID-KLH CONJUGATE VACCINE

Inventor(s)
LIVINGSTON et al.

Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:
Date: May 2, 2006

By:



Joseph A. Coppola (Reg. No. 38,413)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(p) (submission of an information disclosure statement under § 1.97(c)) fee of **\$180.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Respectfully submitted,

Dated: May 2, 2006

By:


Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON LLP
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646

05/08/2006 SFELEKE1 00000046 110600 10070665

02 FC:1806 180.00 DA



**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT PTO - 1449 FORM**

ATTY. DOCKET NO.
2653/56

SERIAL NO.
10/070,665

APPLICANT
LIVINGSTON et al.

FILING DATE
December 16, 2002

GROUP
1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Livingston et al., "Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy", Cancer Immunol Immunotherap (2005) 54: 1018-1025
		Krug et al., "Vaccination of small cell lung cancer patients with polysialic acid or <i>N</i> -Propionylated Polysialic acid conjugated to keyhole limpet hemocyanin", Clinical Cancer Research, Vol. 10, 916-923, February 1, 2004

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	